Company profilePharmaceutical#1010 of 1,318 in Pakistan✓ No DRAP alerts

BM Biotech Pakistan

Pharmaceutical company · 3 brands · 2 molecules

Ranked #15 of 24 companies in Hormone Regulators

3 registered products 2 pharmaceutical brands 2 distinct molecules 0 DRAP alerts

Company overview

3
registered products
2
pharmaceutical brands
2
distinct molecules
4
therapeutic classes
0
DRAP alerts

BM Biotech Pakistan is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 3 product registrations across 2 distinct molecules. Its portfolio is concentrated in Hormone Regulators and Skin Conditions. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by BM

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Hormone Regulators 1

Top molecules by brand count

Therapeutic classes

Hormone Regulators · 1Skin Conditions · 1Endocrine Hormone Therapy · 1Cancer · 1

Conditions treated

Hormonal Therapy · 1Infection/Allergy · 1Oncology · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid3 products · Rs 862.5 – Rs 2,363
Median across source: Rs 929.75

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HIGH - Q INTERNATIONAL holds 140 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAmlodipineAnastrozoleAprepitant
Martin Dow Marker Limited holds 103 molecules not in this portfolio
000 I.UAlprazolamAlteplaseAmlodipineApixabanArtemether
SEARLE PAKISTAN (PVT.) LTD. holds 238 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for BM

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.